MPL Antikörper

Produktnummer ABIN969542

Produktdetails anti-MPL Antikörper

Target: MPL (Myeloproliferative Leukemia Virus Oncogene (MPL))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser MPL Antikörper ist unkonjugiert

Applikation: ELISA, Flow Cytometry (FACS)

Verwendungszweck: MPL Antibody

Aufreinigung: Purified antibody

Immunogen: Purified recombinant fragment of human MPL expressed in E. Coli.

Klon: 1H2

Isotyp: IgG2b

Anwendungsinformationen

Applikationshinweise:

ELISA: 1/10000

FCM: 1/200 - 1/400

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Purified antibody in PBS with 0.05 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.

Referenzen für anti-MPL Antikörper (ABIN969542)

Marty, Chaligné, Lacout, Constantinescu, Vainchenker, Villeval: "Ligand-independent thrombopoietin mutant receptor requires cell surface localization for endogenous activity." in: The Journal of biological chemistry, Vol. 284, Issue 18, pp. 11781-91, (2009) (PubMed).

Blackford, Parmigiani, Kensler, Wolfgang, Jones, Zhang, Parsons, Lin, Leary, Eshleman, Goggins, Jaffee, Iacobuzio-Donahue, Maitra, Klein, Cameron, Olino, Schulick, Winter, Vogelstein, Velculescu, Kinzler, Hruban: "Genetic mutations associated with cigarette smoking in pancreatic cancer." in: Cancer research, Vol. 69, Issue 8, pp. 3681-8, (2009) (PubMed).

Details zu MPL

Target: MPL (Myeloproliferative Leukemia Virus Oncogene (MPL))

Andere Bezeichnung: MPL (MPL Produkte)

Synonyme: C-MPL antikoerper, CD110 antikoerper, MPLV antikoerper, THCYT2 antikoerper, TPOR antikoerper, TPO-R antikoerper, c-mpl antikoerper, c-mpl-I antikoerper, c-mpl-II antikoerper, hlb219 antikoerper, MPL antikoerper, mpll antikoerper, tpor antikoerper, tpor.b antikoerper, MPL proto-oncogene, thrombopoietin receptor antikoerper, myeloproliferative leukemia virus oncogene antikoerper, MPL antikoerper, Mpl antikoerper, mpl antikoerper

Hintergrund:

Description: In 1990 an oncogene, v-mpl, was identified from the murine myeloproliferative leukemia virus that was capable of immortalizing bone marrow hematopoietic cells from different lineages. In 1992 the human homologue, named, c-mpl, was cloned. Sequence data revealed that c-mpl encoded a protein that was homologous with members of the hematopoietic receptor superfamily. Presence of anti-sense oligodeoxynucleotides of c-mpl inhibited megakaryocyte colony formation. The ligand for c-mpl, thrombopoietin, was cloned in 1994. Thrombopoietin was shown to be the major regulator of megakaryocytopoiesis and platelet formation. The protein encoded by the c-mpl gene, CD110, is a 635 amino acid transmembrane domain, with two extracellular cytokine receptor domains and two intracellular cytokine receptor box motifs . TPO-R deficient mice were severely thrombocytopenic, emphasizing the important role of CD110 and thrombopoietin in megakaryocyte and platelet formation. Upon binding of thrombopoietin CD110 is dimerized and the JAK family of non-receptor tyrosine kinases, as well as the STAT family, the MAPK family, the adaptor protein Shc and the receptors themselves become tyrosine phosphorylated.

Aliases: MPLV, TPOR, C-MPL, CD110

Molekulargewicht: 71.2kDa

Gen-ID: 4352

HGNC: 4352

UniProt: P40238

Pathways: JAK-STAT Signalweg